The recent letter by Parsa1 regarding visual function and the clinical behavior of optic pathway glioma (OPG) raises several critically significant points worthy of clarification and further discussion. The importance of this debate should not be understated as it is crucial to our approach to the treatment of young children at risk for irreversible vision loss. For clarity, we will address each of Parsa's points systematically.